Condition: Bacterial Overgrowth Syndrome Small Bowel · Heart Failure with Preserved Ejection Fraction · Sponsor: I.M. Sechenov First Moscow State Medical University
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.
This description comes directly from the study's public registry record.
Konstantin Ivashkin · +7 926 213 58 33 · ivashkin_k_v@staff.sechenov.ru
Elena Bueverova · +7 916 526 6245 · bueverova_e_l@staff.sechenov.ru
Always discuss trial participation with your own doctor first.
| Moscow | Moscow, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06652087